Soluble CD40L (CD154) is increased in patients with shock

Area of Science:

• Critical Care Medicine
• Immunology
• Biochemistry

Background:

• Soluble CD40L (sCD40L) is implicated in murine sepsis.
• Systemic Inflammatory Response Syndrome (SIRS) and shock are critical conditions.
• Understanding inflammatory markers in shock is crucial for patient management.

Purpose of the Study:

• To quantify plasma levels of sCD40L in critically ill patients with SIRS and shock.
• To compare sCD40L levels in patients with and without sepsis.
• To investigate the relationship between sCD40L and disease severity.

Main Methods:

• Prospective observational cohort study.
• Inclusion of 53 patients with SIRS and shock, and 7 age-matched controls.
• Enzyme-linked immunosorbent assay (ELISA) for plasma sCD40L quantification.

Main Results:

• Healthy controls had a mean sCD40L level of 0.18 ± 0.03 ng/ml.
• Patients with non-septic shock (0.72 ± 0.18 ng/ml) and septic shock (0.50 ± 0.1 ng/ml) showed significantly higher sCD40L levels.
• No significant difference in sCD40L levels was observed between septic and non-septic shock groups or across different APACHE scores.

Conclusions:

• Plasma sCD40L is elevated in patients experiencing shock due to both septic and non-septic causes.
• The functional significance of elevated sCD40L in shock requires further investigation.
• sCD40L may serve as a potential biomarker in critical illness, but its precise role needs elucidation.